{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:23:17Z","timestamp":1783401797776,"version":"3.54.6"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["R01GM140154"],"award-info":[{"award-number":["R01GM140154"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["469954457"],"award-info":[{"award-number":["469954457"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU06.716"],"award-info":[{"award-number":["TTU06.716"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2023\/07455-5"],"award-info":[{"award-number":["2023\/07455-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/08260-8"],"award-info":[{"award-number":["2021\/08260-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2024\/07723-2"],"award-info":[{"award-number":["2024\/07723-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2202\/07275-4"],"award-info":[{"award-number":["2202\/07275-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.compbiomed.2025.110990","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:02:09Z","timestamp":1756375329000},"page":"110990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"PA","title":["Dona Flor and her two husbands: Discovery of novel HDAC6\/AKT2 inhibitors for myeloid cancer treatment"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2382-534X","authenticated-orcid":false,"given":"Karoline B.","family":"Waitman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holli-Joi","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-4665","authenticated-orcid":false,"given":"Jorge A.E.G.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-3464","authenticated-orcid":false,"given":"Rodolpho C.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5811-6485","authenticated-orcid":false,"given":"Vin\u00edcius A.M.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleber C.","family":"Melo-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hilscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica F.Z. J.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-7787","authenticated-orcid":false,"given":"Maur\u00edcio T.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia V.","family":"Costa-Lotufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o A.","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Schutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales","family":"Kronenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-1748","authenticated-orcid":false,"given":"Vinicius M.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Parise-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-7036","authenticated-orcid":false,"given":"Eugene N.","family":"Muratov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2025.110990_bib1","unstructured":"Amado J. Dona Flor E Seus Dois Maridos: Hist\u00f3ria Moral E De Amor. first ed. Companhia de Bolso, S\u00e3o Paulo.."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110990_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/d41573-021-00022-w","article-title":"The most successful oncology drug portfolios of the past decade","volume":"20","author":"Paliouras","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.110990_bib4","article-title":"Cancer","author":"Roser","year":"2015","journal-title":"Our World in Data"},{"issue":"November 2022","key":"10.1016\/j.compbiomed.2025.110990_bib5","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110990_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"19","key":"10.1016\/j.compbiomed.2025.110990_bib9","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology : challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110990_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4155\/fmc-2021-0276","article-title":"New kinase and HDAC hybrid inhibitors: recent advances and perspectives","volume":"14","author":"Waitman","year":"2022","journal-title":"Future Med. Chem."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110990_bib11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","article-title":"CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial","volume":"102","author":"Oki","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.compbiomed.2025.110990_bib12","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.compbiomed.2025.110990_bib13","article-title":"NCT03874234 clinical trial","year":"2021","journal-title":"ClinicalTrials.Gov"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110990_bib14","first-page":"1019","article-title":"AKT as a therapeutic target for cancer","volume":"Res79","author":"Song","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110990_bib15","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.7150\/ijbs.93375","article-title":"HDAC inhibition sensitize hepatocellular carcinoma to lenvatinib via suppressing AKT activation","volume":"20","author":"Yan","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-53","article-title":"Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia\/lymphoma","volume":"6","author":"Dong","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.110990_bib17","article-title":"America) P (Pharmaceutical R and M of. PHRMA Industry Profile 2021","year":"2021","journal-title":"2021 Profile Biopharma. Res. Industry"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110990_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.110990_bib19","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c01684","article-title":"Can machine learning overcome the 95% failure rate and reality that only 30% of approved cancer drugs meaningfully extend patient survival?","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.compbiomed.2025.110990_bib20","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110990_bib21","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.drudis.2020.09.021","article-title":"Recent progress on cheminformatics approaches to epigenetic drug discovery","volume":"25","author":"Sessions","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.drudis.2021.10.014","article-title":"Knowledge-based approaches to drug discovery for rare diseases","volume":"27","author":"Alves","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/acs.chemrestox.0c00186","article-title":"Pred-skin: a web portal for accurate prediction of human skin sensitizers","volume":"34","author":"Borba","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110990_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10003","article-title":"Design and prediction of novel pyrazole derivatives as potential anti-cancer compounds based on 2D-2D-QSAR study against PC-3, B16F10, K562, MDA-MB-231, A2780, ACHN and NUGC cancer cell lines","volume":"8","author":"Bennani","year":"2022","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110990_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03640","article-title":"QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2","volume":"6","author":"Umar","year":"2020","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/medicines6020045","article-title":"QSAR prediction model to search for compounds with selective cytotoxicity against oral cell cancer","volume":"6","author":"Nagai","year":"2019","journal-title":"Medicines"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib27","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1021\/acsomega.8b03693","article-title":"Multicellular target QSAR model for simultaneous prediction and design of anti-pancreatic cancer agents","volume":"4","author":"Speck-Planche","year":"2019","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/07391102.2019.1574603","article-title":"QSAR studies on the human sirtuin 2 inhibition by non-covalent 7,5,2-anilinobenzamide derivatives","volume":"38","author":"Ferreira","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110990_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jcim.1c01554","article-title":"Discovery of anticancer hybrid molecules by supervised machine learning models and in vitro validation in drug resistant chronic myeloid leukemia cells","volume":"62","author":"Melge","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-2858-1-3","article-title":"Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models","volume":"1","author":"Bohari","year":"2011","journal-title":"Org Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110990_bib31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jare.2016.03.010","article-title":"Quantitative structure\u2013activity relationship study on potent anticancer compounds against MOLT-4 and P388 leukemia cell lines","volume":"7","author":"Arthur","year":"2016","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.compbiomed.2025.110990_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115935","article-title":"HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents","volume":"263","author":"Waitman","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7471","key":"10.1016\/j.compbiomed.2025.110990_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110990_bib34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110990_bib35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020318","article-title":"HDAC6\u2014an emerging target against chronic myeloid leukemia?","volume":"12","author":"Losson","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41375-021-01392-1","article-title":"PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression","volume":"36","author":"Yuan","year":"2022","journal-title":"Leukemia"},{"issue":"W1","key":"10.1016\/j.compbiomed.2025.110990_bib38","doi-asserted-by":"crossref","first-page":"W356","DOI":"10.1093\/nar\/gkx374","article-title":"PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.compbiomed.2025.110990_bib39","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad014","article-title":"Comprehensive assessment of nine target prediction web services: which should we choose for target fishing?","volume":"24","author":"Ji","year":"2023","journal-title":"Briefings Bioinf."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110990_bib41","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/jm4004285","article-title":"QSAR modeling: where have you been? Where are you going to?","volume":"57","author":"Cherkasov","year":"2014","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110990_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nchembio.1881","article-title":"Curation of chemogenomics data","volume":"11","author":"Fourches","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110990_bib43","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/acs.jcim.6b00055","article-title":"QSAR-driven discovery of novel chemical scaffolds active against Schistosoma mansoni","volume":"56","author":"Melo-Filho","year":"2016","journal-title":"J. Chem. Inf. Model."},{"issue":"6\u20137","key":"10.1016\/j.compbiomed.2025.110990_bib44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/qsar.200860117","article-title":"Consensus QSAR modeling of phosphor-containing chiral AChE inhibitors","volume":"28","author":"Kuz\u2019min","year":"2009","journal-title":"QSAR Comb. Sci."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110990_bib45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10822-008-9211-x","article-title":"The effects of characteristics of substituents on toxicity of the nitroaromatics: HiT QSAR study","volume":"22","author":"Kuz\u2019min","year":"2008","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"5\u20136","key":"10.1016\/j.compbiomed.2025.110990_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/1062936X.2011.569950","article-title":"Qsar analysis of the toxicity of nitroaromatics in tetrahymena pyriformis: structural factors and possible modes of action","volume":"22","author":"Artemenko","year":"2011","journal-title":"SAR QSAR Environ. Res."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110990_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/ci100176x","article-title":"Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research","volume":"50","author":"Fourches","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"19","key":"10.1016\/j.compbiomed.2025.110990_bib48","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1021\/acs.chemmater.4c00981","article-title":"Trust not verify? The critical need for data curation standards in materials informatics","volume":"36","author":"Hart","year":"2024","journal-title":"Chem. Mater."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110990_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/minf.201000001","article-title":"Application of random forest and multiple linear regression techniques to QSPR prediction of an aqueous solubility for military compounds","volume":"29","author":"Kovdienko","year":"2010","journal-title":"Mol. Inform"},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110990_bib50","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/acs.jcim.8b00124","article-title":"Multi-descriptor read across (MuDRA): a simple and transparent approach for developing accurate quantitative structure-activity relationship models","volume":"58","author":"Alves","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2025.110990_bib51","unstructured":"ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD). GUIDANCE DOCUMENT ON THE VALIDATION OF (QUANTITATIVE) STRUCTURE-ACTIVITY RELATIONSHIP [(Q)SAR] MODELS. Environment health and safety publications, Series Testing Assessment, No. 69 [Internet]. France. Available from: https:\/\/read.oecd-ilibrary.org\/environment\/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models_9789264085442-en.."},{"issue":"6\u20137","key":"10.1016\/j.compbiomed.2025.110990_bib57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","article-title":"Best practices for QSAR model development, validation, and exploitation","volume":"29","author":"Tropsha","year":"2010","journal-title":"Mol. Inform"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110990_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/02611929211029635","article-title":"Curated data In - trustworthy In Silico models out: the impact of data quality on the reliability of artificial intelligence models as alternatives to animal testing","volume":"49","author":"Alves","year":"2021","journal-title":"Altern. Lab. Anim."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110990_bib59","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/acs.jcim.4c00049","article-title":"Combining IC50 or Ki values from different sources is a source of significant noise","volume":"64","author":"Landrum","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110990_bib60","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1021\/acs.jmedchem.3c02446","article-title":"Pharmacokinetics profiler (PhaKinPro): model development, validation, and implementation as a web tool for triaging compounds with undesired pharmacokinetics profiles","volume":"67","author":"Rath","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"March","key":"10.1016\/j.compbiomed.2025.110990_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.compbiomed.2025.110990_bib63","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110990_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1039\/C4MD00406J","article-title":"Synthesis and evaluation of phenoxymethylbenzamide analogues as anti-trypanosomal agents","volume":"6","author":"Manos-Turvey","year":"2015","journal-title":"Medchemcomm"},{"key":"10.1016\/j.compbiomed.2025.110990_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112291","article-title":"Purine\/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors","volume":"196","author":"Nepali","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.110990_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8797206","article-title":"HDAC inhibitors as epigenetic regulators of the immune System: impacts on cancer therapy and inflammatory diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.compbiomed.2025.110990_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111755","article-title":"Discovery of a potent histone deacetylase (HDAC) 3\/6 selective dual inhibitor","volume":"184","author":"Soumyanarayanan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"51","key":"10.1016\/j.compbiomed.2025.110990_bib69","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110990_bib70","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.jmedchem.0c01967","article-title":"HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates","volume":"64","author":"Mak","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.110990_bib71","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.compbiomed.2025.110990_bib73","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1021\/acs.jmedchem.7b00745","article-title":"Design, synthesis, and biological evaluation of novel type I1\/2 p38\u03b1 MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time by interfering with the R-Spine","volume":"60","author":"Walter","year":"2017","journal-title":"J. Med. Chem."},{"issue":"48","key":"10.1016\/j.compbiomed.2025.110990_bib74","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.biochem.9b00786","article-title":"One-Atom substitution enables direct and continuous monitoring of histone deacylase activity","volume":"58","author":"Zessin","year":"2019","journal-title":"Biochemistry"},{"issue":"66","key":"10.1016\/j.compbiomed.2025.110990_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/stke.2001.66.pe1","article-title":"PDK2: a complex tail in one akt","volume":"2001","author":"Chan","year":"2001","journal-title":"Sci. Signal."},{"issue":"17","key":"10.1016\/j.compbiomed.2025.110990_bib76","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.2174\/1871520620666200627204857","article-title":"Histone deacetylase inhibitor trichostatin A suppresses cell proliferation and induces apoptosis by regulating the PI3K\/AKT signalling pathway in gastric cancer cells","volume":"20","author":"An","year":"2020","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib77","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-7-812","article-title":"Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells","volume":"7","author":"Morgan","year":"2014","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110990_bib78","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10637-019-00794-4","article-title":"Cotargeting the JAK\/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms","volume":"38","author":"Hao","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.compbiomed.2025.110990_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173057","article-title":"Vorinostat upregulates MICA via the PI3K\/Akt pathway to enhance the ability of natural killer cells to kill tumor cells","volume":"875","author":"Xia","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"19","key":"10.1016\/j.compbiomed.2025.110990_bib80","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1074\/jbc.M602060200","article-title":"Autophosphorylation of Akt at threonine 72 and serine 246: a potential mechanism of regulation of Akt kinase activity","volume":"281","author":"Li","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110990_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136193","article-title":"Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT\/mTOR signaling","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"51","key":"10.1016\/j.compbiomed.2025.110990_bib82","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.compbiomed.2025.110990_bib83","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110990_bib84","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-Group-Containing drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J. Med. Chem."},{"issue":"50","key":"10.1016\/j.compbiomed.2025.110990_bib85","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1038\/sj.onc.1209087","article-title":"AKT crystal structure and AKT-specific inhibitors","volume":"24","author":"Kumar","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110990_bib86","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jcim.6b00129","article-title":"Trust, but verify II: a practical guide to chemogenomics data curation","volume":"56","author":"Fourches","year":"2016","journal-title":"J. Chem. Inf. Model."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.110990_bib87","first-page":"1","article-title":"Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods","volume":"5","author":"Riniker","year":"2013","journal-title":"J. Cheminf."},{"issue":"34","key":"10.1016\/j.compbiomed.2025.110990_bib88","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.2174\/138161207782794257","article-title":"Predictive QSAR modeling workflow, model applicability domains, and virtual screening","volume":"13","author":"Tropsha","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.compbiomed.2025.110990_bib89","series-title":"Methods Mol Biol","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-61779-080-5_20","article-title":"Sensitivity assays: the MTT assay [Internet]","author":"van Meerloo","year":"2011"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02446-4","article-title":"Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors","volume":"11","author":"Carlos","year":"2025","journal-title":"Cell Death Discov."},{"issue":"24","key":"10.1016\/j.compbiomed.2025.110990_bib91","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-Based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110990_bib92","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.110990_bib93","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.110990_bib94","first-page":"1","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006","journal-title":"Proc. 2006 ACM\/IEEE Conf. Supercomput."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110990_bib95","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110990_bib96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110990_bib97","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u00b7log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110990_bib98","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phis. Review A"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110990_bib99","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1063\/1.447334","article-title":"A unified formulation of the constant temperature molecular dynamics methods","volume":"81","author":"Nos\u00e9","year":"1984","journal-title":"J. Chem. Phys."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110990_bib100","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/00268979600100761","article-title":"Explicit reversible integrators for extended systems dynamics","volume":"87","author":"Martyna","year":"1996","journal-title":"Mol. Phys."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110990_bib101","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110990_bib102","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expet Opin. Drug Discov."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525013423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525013423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:07:58Z","timestamp":1772816878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525013423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":96,"alternative-id":["S0010482525013423"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110990","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.30.626092","asserted-by":"object"}]},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dona Flor and her two husbands: Discovery of novel HDAC6\/AKT2 inhibitors for myeloid cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110990"}}